Pevion Biotech Ltd.

Pevion Biotech Ag

Istituto Superiore Di Sanita

Mymetics Corporation

Institut National De La Sante Et De La Recherche Medicale

Intercell Ag

Novadigm Therapeutics, Inc.

Pluschke, Gerd Et Al.

Biolife Science Qld Limited

Rinaldo Zurbriggen

Silvia Rasi

Andreas Kammer

John Anthony Robinson

Antonio Cassone

Mario Amacker

Gerd Pluschke

Flavia De Bernardis

Sylvain Fleury

Morgane Bomsel

Christian Moser

Annabelle Freund-Renard

Mueller Markus

Joseph Brunner

Sonia Vadrucci

Ursula Kienzl

Nicole Westerfeld

Josef Brunner

Sonja Vadrucci

The present invention relates to an isolated truncated form of the secretory aspartyl proteinase 2, as well as to nucleic acid molecules encoding same. The present invention also relates to a composition comprising an isolated truncated form of the secretory aspartyl proteinase 2, as well as to nucleic acid molecules encoding same.

Truncated secretory aspartyl proteinase 2

The present invention relates to a virosome-like vesicle comprising at least a gp41-derived antigen or an analogue thereof, said gp41-derived antigen being located to the external surface of and/or encapsulated inside said vesicle and being in a convenient configuration for conferring said virosome-like vesicle with an ability to induce an immune response against a gp41 protein or a human immunodeficiency virus (HIV).

Virosome-like vesicles comprising gp41-derived antigens

The present invention includes fusion peptides comprising fragments of the cancer-related protein Her2/neu, methods of preparing such fusion peptides, virosomes comprising such fusion peptides, and uses of such fusion peptides or virosomes for the prevention, treatment or amelioration of a cancer characterized by expression or over-expression of the Her2/neu protein.

Multiepitope vaccine for Her2/neu-associated cancers

The present invention relates to a novel adjuvant system that generates an efficient immune response against antigens of various origins while reducing the risk of toxic side effects attendant to the use of known adjuvants. The novel adjuvant of the present invention comprises virosomes and allows antigenic molecules to be bound to or encapsulated in a variety of delivery vehicles which are easier to prepare for virosomes.

Trans-adjuvant system

The present invention relates to virosomes comprising hemagglutinin (HA) with improved fusion activity. Preferably, the HA comprised in said virosomes was derived from influenza virus produced in a cell line. The present invention also relates to compositions and a kit comprising the virosomes according to the invention. Further, the present invention relates to uses and methods involving said virosomes, as well as to a method for preparing same.

Virosomes comprising hemagglutinin derived from an influenza virus produced in a cell line, compositions, methods of manufacturing, use thereof

The present invention relates to methods for synthesizing conformationally constrained peptides and cyclic peptidomimetics obtainable by these methods which are conformationally constrained due an internal cross-link. This cross-link is formed between the side chain of an amino acid residue or analog and a (2S, 4S)4-functionalized proline residue. The invention further relates to the use of (2S, 4S)-4-functionalized proline residues as building units in the synthesis of such peptidomimetics and to the use thereof as antigens, alone or in combination with suitable immunopotentiating delivery systems, for example immunopotentiating reconstituted influenza virosomes to elicit an immune response in a mammal. Moreover, the invention also relates to pharmaceutical compositions containing the same.

Method for synthesizing conformationally constrained peptides, peptidomimetics and the use thereof as synthetic vaccines

The present invention provides novel adjuvant systems for the potentiation of immune responses against antigenic targets.

Compositions and methods for the potentiation of immune responses against target antigens

The present invention relates to novel fusogenic vesicles as highly efficient and versatile encapsulation systems for delivering a substance of choice, such as nucleic acids, proteins, peptides, antigens, pharmaceutical drugs and cosmetic agents to cells and tissues.

High-efficiency fusogenic vesicles, methods of producing them, and pharmaceutical compositions containing them

The invention presents vaccine formulations comprising highly antigenic epitopes identified within the semi-conserved loop-I of domain III that are capable of eliciting parasite growth inhibitory antibodies. The cyclized or linear peptides can be applied by known adjuvants or be encapsulated by or attached onto the surface of liposomes or virosomes (IRIVs) which serve as human compatible antigen delivery systems. Both cyclized and linear versions of the peptide antigens are surprisingly effective in eliciting immune responses that are cross-reactive with parasite-expressed AMA-1.

Compositions and methods for the generation of protective immune responses against malaria

Growing community of inventors

Schmitten, Switzerland

Rinaldo Zurbriggen